Streetbeat News

Regulatory

ICE

The SEC has charged Intercontinental Exchange, Inc. (ICE) a $10 million penalty for failing to inform the Commission of a cyber intrusion affecting nine of its subsidiaries, including the New York Stock Exchange, in a timely manner.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 1:07 pm

PTIX

Protagenic Therapeutics reported safety data from the single dose portion of its Phase 1 trial involving PT00114, with no clinically-relevant adverse events. The multiple dose portion of the trial is set to commence.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 1:03 pm

NAOV

NanoVibronix, Inc. (NASDAQ:NAOV) announced the start of the pilot phase of a clinical trial for its UroShield device at the University of Michigan. This trial is part of a broader study to further validate the efficacy of UroShield.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:36 pm

CBOE

ETHUSD

Bloomberg analyst James Seyffart indicated that the launch of spot Ethereum ETFs could still be weeks away, despite recent filings by issuers like Fidelity, VanEck, Invesco/Galaxy, Ark/21Shares, and Franklin. The primary change in these filings was the removal of staking-related content. The approval odds remain at 75%, but the SEC's extensive review process could delay the launch.

Portfolio Pulse from Murtuza Merchant

May 22, 2024 | 12:20 pm

TNXP

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) will deliver an oral presentation and present two posters at the ASCP Annual Meeting from May 28-31, 2024. The presentation will focus on Tonmya™ (TNX-102 SL) for fibromyalgia, with NDA preparation in progress. The posters will highlight other TNX-102 SL programs in clinical development, including Long COVID and Acute Stress Disorder.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:18 pm

INDP

Indaptus Therapeutics has successfully advanced its Phase 1 trial for Decoy20, a novel immuno-oncology therapy targeting advanced solid tumors. The trial confirmed the 'Pulse-Prime' hypothesis and identified a tolerable single dose for multi-dosing, which will be presented at ASCO.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:16 pm

ANL

Adlai Nortye has dosed the first patient in a randomized Phase II clinical trial of Palupiprant for the treatment of locally advanced rectal cancer in combination with radiation therapy.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:13 pm

ALZN

Alzamend Neuro, Inc. (NASDAQ:ALZN) has been granted an extension by the Nasdaq Hearings Panel to continue its listing on the Nasdaq Capital Market. The company must demonstrate compliance with the stockholder equity requirement of at least $2.5 million by September 23, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:09 pm

ESPR

The European Commission has approved NILEMDO (bempedoic acid) and its combination with ezetimibe, NUSTENDI, for treating hypercholesterolemia and reducing cardiovascular risk. This approval makes bempedoic acid the first and only LDL-C lowering treatment indicated for primary and secondary prevention of cardiovascular events.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:08 pm

AWAY

LYFT

OND

UBER

Uber and Lyft drivers in Minnesota will receive higher pay starting January 1, 2025, due to a new law. The legislation, supported by Governor Tim Walz, sets minimum rates and offers protections for drivers. This could increase costs for riders. Uber reported a 15% revenue growth in Q1 2024 but missed analyst expectations. Uber's stock gained over 63% in the last 12 months, while Lyft's stock gained 98%. Investors can gain exposure to these stocks via ProShares On-Demand ETF (OND) and Amplify Travel Tech ETF (AWAY).

Portfolio Pulse from Anusuya Lahiri

May 22, 2024 | 11:48 am